

54. Devogelaer JP. Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. *Rheum Dis Clin North Am* 2007; 32: 733–757.
55. Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int* 2007; 18: 1319–1328.
56. Tan B, Li P, Lv H, et al. Vitamin D and BMD in Chinese IBD patients. *Journal of Digestive Diseases* 2014; 15: 116–123.
57. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. *Gastroenterology* 2010; 138: 896–904.
58. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. *Am J Gastroenterol* 2011; 106: 1209–1218.
59. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? *J Bone Miner Res* 2010; 25: 786–795.
60. Sgambato D, Gimigliano F, De Musis C, et al. Bone alterations in inflammatory bowel diseases. *World J Clin Cases* 2019; 7: 1908–1925.